Xspray Pharma licenses patent rights to Handa Therapeutics, secures royalty agreement
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Revenue increased 11.4 per cent to Rs. 8,545 crore
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
A triple-action Formula for comprehensive respiratory relief
Subscribe To Our Newsletter & Stay Updated